Minakem Generic APIs Minakem Generic APIs

X
menu

    Market Place

    Market Place

    Post Enquiry

    Post Enquiry
    menu
    [{"orgOrder":0,"company":"SAKK","sponsor":"Oasmia Pharmaceutical","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"Oasmia Pharmaceutical AB Signs Phase 1b Trial Agreement with SAKK","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase I","country":"SWITZERLAND","productType":"Small molecule","productStatus":"Approved","date":"June 2020","url1":"","url2":"","graph1":"Oncology","graph2":"Phase I"},{"orgOrder":0,"company":"SAKK","sponsor":"Intensity Therapeutics","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"Intensity Therapeutics, SAKK ink Agreement to Conduct Phase 2 Trial in Early-stage Breast Cancer in Europe for INT230-6","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase II","country":"SWITZERLAND","productType":"Small molecule","productStatus":"Approved","date":"May 2024","url1":"","url2":"","graph1":"Oncology","graph2":"Phase II"}]

    Find Clinical Drug Pipeline Developments & Deals by SAKK

    Menu

    SAKK

    EVENTS

    • Webinars & Exhibitions

    PRESENTATION(s)

    VIDEO(s)

    DIGITAL CONTENT

    DEVELOPMENTS

    PharmaCompass
    Loading...

    All Data

    Previous
    Next
    Filters Filter
    ×
    FILTER:
    filter Company
      filter Sponsor
        filter Country
          filter Therapeutic Area
            filter Study Phase

              Active Filter(s):

              refreshFilters
              refreshReset Filter
              refresh Reset Filter
              price-trend All Developments

              Companies By Therapeutic Area

              Development Status

              SAKK

              Contact Supplier
              • Deals
              Virtual Booth Upload your Marketing & Sales content on your company Virtual Booth, click HERE
              Post an Enquiry Post an Enquiry
              Flag Switzerland
              Virtual Booth Virtual Booth
              Digital Content Digital Content

              Intensity Therapeutics, SAKK ink Agreement to Conduct Phase 2 Trial in Early-stage Breast Cancer in Europe for INT230-6

              Details:

              The collaboration aims to conduct a phase 2 trial evaluating clinical and biological effects of intratumoral INT230-6, a formulation consisting of 2-hydroxybenzoyl amino octanoate combined with cisplatin and vinblastine in early-stage triple-negative breast cancer.

              Lead Product(s): Vinblastine Sulfate,Cisplatin,2-hydroxybenzoyl Amino Octanoate

              Therapeutic Area: Oncology Product Name: INT230-6

              Highest Development Status: Phase II Product Type: Small molecule

              Recipient: Intensity Therapeutics

              Deal Size: Undisclosed Upfront Cash: Undisclosed

              Deal Type: Collaboration May 13, 2024

              ASK
              US
              PHARMACOMPASS
              Upload
              your Pipeline Activity

              SAKK

              Contact Supplier
              • Deals
              Virtual Booth Upload your Marketing & Sales content on your company Virtual Booth, click HERE
              Post an Enquiry Post an Enquiry
              Flag Switzerland
              Virtual Booth Virtual Booth
              Digital Content Digital Content

              Oasmia Pharmaceutical AB Signs Phase 1b Trial Agreement with SAKK

              Details:

              SAKK is the legal sponsor of the project and responsible to conduct the phase 1B trial. Oasmia’s main role in the project is to supply its formulation of docetaxel and carry the cost of the trial, which are deemed not material to Oasmia.

              Lead Product(s): Docetaxel

              Therapeutic Area: Oncology Product Name: Undisclosed

              Highest Development Status: Phase I Product Type: Small molecule

              Recipient: Oasmia Pharmaceutical

              Deal Size: Undisclosed Upfront Cash: Undisclosed

              Deal Type: Agreement June 08, 2020

              ASK
              US
              PHARMACOMPASS
              Upload
              your Pipeline Activity
              Symbiotec: Global API manufacturer, specializing in Cortico-Steroids & Steroid-Hormone APIs.
              Metrochem has been delivering customized volume & quality products to customers across the world, taking utmost care of their needs.
              Post Enquiry
              POST ENQUIRY